传统抗凝剂由于安全性等原因，在脑梗死的治疗中受到较多限制。阿加曲班作为新型抗凝剂的典型代表之一，具有单靶点、半衰期短、量效稳定等特点，从而全面提高了临床抗凝的安全性。阿加曲班在脑梗死治疗方面积累了大量的研究和证据，但尚缺乏系统的梳理。按照TOAST分型、OCSP分型以及不同的治疗时机，对阿加曲班治疗脑梗死的研究进行分类介绍，以期为脑梗死的抗凝治疗和阿加曲班的临床应用提供更多依据和建议。

Traditional anticoagulants are limited in treatment of cerebral infarction due to safety reasons. As one of the typical representatives of the new anticoagulant, argatroban has the characteristics of single target, short half-life, and stable quantity, thus improving the safety of clinical anticoagulation comprehensively. Argatroban has accumulated a great deal of research and evidence in the treatment of cerebral infarction, but it lacks systematic combing. According to the TOAST classification, OCSP classification, and different treatment timing, the study on argatroban in treatment of cerebral infarction is discussed in this paper, in order to provide more evidence and suggestion for the anticoagulant therapy of cerebral infarction and the clinical application of argatroban.